Associate Professor of Pediatrics, School of Medicine and Public Health
Dr. Capitini leads an NIH-supported laboratory focusing on development of cell-based therapies, including NK cells and CAR T cells, for the treatment of childhood cancers like neuroblastoma and osteosarcoma. The laboratory also manufactures alternatively activated macrophages for complications of hematopoietic stem cell transplant, like graft-versus-host-disease and acute radiation syndrome. In the clinic, Dr. Capitini was a site Principal Investigator for the first multi-center CAR T cell trial, which led to FDA approval of tisagenlecleucel (Kymriah) for the treatment of recurrent/refractory B cell leukemia in children. He remains a site PI for trials testing Kymriah as upfront therapy for high risk B cell leukemias and for treatment of relapsed non-Hodgkin lymphoma.